Celecoxib in Preventing Skin Cancer

Withdrawn before enrolling · Phase 2

Conditions studied: Non-melanomatous Skin Cancer

In brief

RATIONALE: Celecoxib may be effective in preventing skin cancer by decreasing redness caused by exposure to ultraviolet light and changing potential skin cancer biomarkers. It is not yet known whether celecoxib is more effective than a placebo in preventing skin cancer. PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing skin cancer in participants exposed to ultraviolet light.

Key facts

Study ID

NCT00025051

Run by

National Cancer Institute (NCI)

People needed

0

Last updated by the study team

2013-03-22

Who can join

Age: 20 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.